Roivant Sciences Ltd (NASDAQ:ROIV) finished Thursday with a subtraction of -$0.64 to close at $12.55, a downside of -4.85 percent. An average of 10,762,021 shares of common stock have been traded in the last five days. There was a gain of $2.33 in the past week, and it reached a new high 50 times over the past 12 months. The last 20 days have seen an average of 6,541,255 shares traded, while the 50-day average volume stands at 4,530,610.
ROIV stock has increased by 11.56% in the last month. The company shares reached their 1-month lowest point of $9.87 on 09/25/23. With the stock rallying to its 52-week high on 09/28/23, shares of the company touched a low of $3.11 and a high of $13.23 in 52 weeks. It has reached a new high 18 times so far this year and achieved 57.07% or $4.56 in price. In spite of this, the price is down -5.14% from the 52-week high.
Insider Transactions
ROIV stock investors should be aware that Roivant Sciences Ltd (ROIV) stock had its last reported insider trading activity 21 days ago on Sep 08. In this transaction, the insider spent $1,297,382. Chief Accounting Officer, Kumar Rakhi, disposed of 99,350 shares at a price of $12.18 on Sep 08. The insider now owns more than $1,210,083 worth of shares. Prior to that, Chief Operating Officer Venker Eric went on to Sale 5,926 shares at $11.85 each on Sep 06. An amount of $70,223 was transacted.
Valuation Metrics
Roivant Sciences Ltd (ROIV) stock’s beta is 1.15. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 123.25, the price-to-book (PB) ratio at 10.57.
Financial Health
The quick ratio of Roivant Sciences Ltd for the three months ended June 29 was 6.35, and the current ratio was 6.37, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 0.48 and a total debt to equity ratio of 0.54 for the quarter ending June 29. Its gross profit as reported stood at $48.15 million compared to revenue of $61.28 million.
Earnings Surprise
For the three-month period that ended June 29, Roivant Sciences Ltd had $385.07 million in total debt. In the quarter under review, the net income was down than the previous quarter. The company posted a net income of -$291.82 million in the quarter, while revenues of -$33.62 million were shrunk -13.7%. The analyst consensus anticipated Roivant Sciences Ltd’s latest quarter earnings to come in at -$0.3 per share, but it turned out to be -$0.38, a -26.70% surprise. For the quarter, EBITDA amounted to -$270.57 million. Shareholders own equity worth $771.74 million.
Technical Picture
From a technical analysis perspective, let’s take a brief look at Roivant Sciences Ltd (ROIV) price momentum. RSI 9-day as of the close on 28 September was 62.98%, suggesting the stock is Neutral, with historical volatility in this time frame at 114.61%.
As of today, ROIV’s price is $11.74 +22.80% or $2.33 from its 5-day moving average. ROIV is currently trading +8.38% higher than its 20-day SMA and +45.59% higher than its 100-day SMA. However, the stock’s current price level is +8.75% above the SMA50 and +79.29% above the SMA200.
The stochastic %K and %D were 87.95% and 63.27%, respectively, and the average true range (ATR) was 0.76. With the 14-day stochastic at 79.53% and the average true range at 0.68, the RSI (14) stands at 60.13%. The stock has reached 1.48 on the 9-day MACD Oscillator while the 14-day reading was at 1.44.
Analyst Ratings
BofA Securities launched coverage on Roivant Sciences Ltd (NASDAQ: ROIV) in its analyst report released on June 08, 2023. The firm assigned the stock a Neutral rating.
